Held to account

14 Apr 2022 By Jennifer Hughes

Prenetics, supplier of Covid-19 tests to cruise lines, airports and England’s Premier League, has won U.S. approval to float by merging with a blank-cheque firm. But the fast-growing outfit excludes R&D costs from a key financial metric. That’s a warning sign for investors.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)